Understanding economic evidence for the prevention and treatment of atopic eczema
Understanding economic evidence for the prevention and treatment of atopic eczema
BACKGROUND: Atopic eczema is an inflammatory skin condition, with a similar impact on health-related quality of life as other chronic diseases. Increasing pressures on resources within the National Health Service increase the importance of having good economic evidence to inform their allocation.
OBJECTIVES: To educate dermatologists about economic methods with reference to currently available economic evidence on eczema.
METHODS: The role of different types of economic evidence is illustrated by evidence found in a systematic literature search conducted across 12 online databases up to 22 May 2017. Primary empirical studies either reporting the results of a cost-of-illness study or evaluating the cost, utility or full economic evaluation of interventions for preventing or treating eczema were included. Two reviewers independently assessed studies for eligibility and performed data abstraction, with disagreements resolved by a third reviewer. Evidence tables of results were produced for narrative discussion. The reporting quality of economic evaluations was assessed.
RESULTS: Seventy-eight studies (described in 80 papers) were deemed eligible. Thirty-three (42%) were judged to be economic evaluations, 12 (15%) cost analyses, six (8%) utility analyses, 26 (33%) cost-of-illness studies and one a feasibility study (1%). The calcineurin inhibitors tacrolimus and pimecrolimus, as well as barrier creams, had the most economic evidence available. Partially hydrolysed infant formula was the most commonly evaluated prevention.
CONCLUSIONS: The current level of economic evidence for interventions aimed at preventing and treating eczema is limited compared with that available for clinical outcomes, suggesting that greater collaboration between clinicians and economists might be beneficial.
Cost of Illness, Cost-Benefit Analysis, Dermatitis, Atopic/economics, Dermatology/economics, Evidence-Based Medicine/economics, Humans, Quality of Life, State Medicine/economics, United Kingdom
707-716
Sach, T H
5c09256f-ebed-4d14-853a-181f6c92d6f2
McManus, E
0033809d-212e-422b-adfb-a52fce43dcbf
Levell, N J
aa686d9f-6970-4044-b374-e31a3a3e7329
October 2019
Sach, T H
5c09256f-ebed-4d14-853a-181f6c92d6f2
McManus, E
0033809d-212e-422b-adfb-a52fce43dcbf
Levell, N J
aa686d9f-6970-4044-b374-e31a3a3e7329
Sach, T H, McManus, E and Levell, N J
(2019)
Understanding economic evidence for the prevention and treatment of atopic eczema.
British Journal of Dermatology, 181 (4), .
(doi:10.1111/bjd.17696).
Abstract
BACKGROUND: Atopic eczema is an inflammatory skin condition, with a similar impact on health-related quality of life as other chronic diseases. Increasing pressures on resources within the National Health Service increase the importance of having good economic evidence to inform their allocation.
OBJECTIVES: To educate dermatologists about economic methods with reference to currently available economic evidence on eczema.
METHODS: The role of different types of economic evidence is illustrated by evidence found in a systematic literature search conducted across 12 online databases up to 22 May 2017. Primary empirical studies either reporting the results of a cost-of-illness study or evaluating the cost, utility or full economic evaluation of interventions for preventing or treating eczema were included. Two reviewers independently assessed studies for eligibility and performed data abstraction, with disagreements resolved by a third reviewer. Evidence tables of results were produced for narrative discussion. The reporting quality of economic evaluations was assessed.
RESULTS: Seventy-eight studies (described in 80 papers) were deemed eligible. Thirty-three (42%) were judged to be economic evaluations, 12 (15%) cost analyses, six (8%) utility analyses, 26 (33%) cost-of-illness studies and one a feasibility study (1%). The calcineurin inhibitors tacrolimus and pimecrolimus, as well as barrier creams, had the most economic evidence available. Partially hydrolysed infant formula was the most commonly evaluated prevention.
CONCLUSIONS: The current level of economic evidence for interventions aimed at preventing and treating eczema is limited compared with that available for clinical outcomes, suggesting that greater collaboration between clinicians and economists might be beneficial.
This record has no associated files available for download.
More information
Published date: October 2019
Keywords:
Cost of Illness, Cost-Benefit Analysis, Dermatitis, Atopic/economics, Dermatology/economics, Evidence-Based Medicine/economics, Humans, Quality of Life, State Medicine/economics, United Kingdom
Identifiers
Local EPrints ID: 480471
URI: http://eprints.soton.ac.uk/id/eprint/480471
ISSN: 0007-0963
PURE UUID: 28cbca3b-90ca-4ab5-bb32-e901eb6ea6d7
Catalogue record
Date deposited: 02 Aug 2023 17:13
Last modified: 17 Mar 2024 04:20
Export record
Altmetrics
Contributors
Author:
T H Sach
Author:
E McManus
Author:
N J Levell
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics